Clinical Trials
5 trialsNCT06977711 2025-08-05
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
The University of Texas Health Science Center at San Antonio
Phase 1 Recruiting
NCT06643221 2024-10-16
Allo-X
University of Arizona
Phase EARLY_PHASE1 Recruiting
NCT05796271 2024-02-29
Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn
NCT03458546 2024-02-21
Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma
The University of Texas Health Science Center at San Antonio
Phase 1 Completed
NCT01888952 2017-02-27
Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)
The University of Texas Health Science Center at San Antonio
Phase EARLY_PHASE1 Completed